FBIOP

Quote

Short

News

Articles

Message Board

Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ : FBIOP ) News

News Releases

FBIOP News Releases

May 29, 2026 05:20:13 pm

SeekingAlpha

Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?

May 18, 2026 08:30:00 am

GlobeNewswire

Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference

May 14, 2026 04:10:00 pm

GlobeNewswire

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 04, 2026 08:30:00 am

GlobeNewswire

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

March 31, 2026 04:05:00 pm

GlobeNewswire

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

March 30, 2026 04:05:00 pm

GlobeNewswire

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

February 23, 2026 09:24:14 am

GlobeNewswire

UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

February 23, 2026 08:30:00 am

GlobeNewswire

Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

January 13, 2026 07:45:00 am

GlobeNewswire

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

December 15, 2025 08:00:00 am

GlobeNewswire

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account